Oramed Pharmaceuticals Inc.
Clinical-stage company developing oral drug delivery for injectable medications.
ORMP | TA
Overview
Corporate Details
- ISIN(s):
- US68403P2039
- LEI:
- Country:
- Israel
- Address:
- 20 Mamilla Avenue, 9414904 Jerusalem
- Website:
- https://www.oramed.com
- Sector:
- Manufacturing
Description
Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-07-18 14:52 |
Other Report or Announcement
|
English | 1.4 MB | ||
| 2025-07-18 14:52 |
Other Report or Announcement
|
English | 36.4 KB | ||
| 2025-07-18 14:51 |
Other Report or Announcement
|
English | 448.1 KB | ||
| 2025-07-18 14:51 |
Other Report or Announcement
|
English | 36.4 KB | ||
| 2025-07-18 14:50 |
Other Report or Announcement
|
English | 359.9 KB | ||
| 2025-07-18 14:50 |
Other Report or Announcement
|
English | 36.4 KB | ||
| 2025-06-10 11:06 |
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Reznick Yehuda
|
English | 574.4 KB | ||
| 2025-06-10 11:06 |
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Reznick Yehuda
|
English | 36.2 KB | ||
| 2025-05-22 08:30 |
Form 8-K-a one-year extension of the Company’s current stock buyback program
|
Hebrew (modern) | 92.1 KB | ||
| 2025-05-22 08:30 |
Form 8-K-a one-year extension of the Company’s current stock buyback program
|
Hebrew (modern) | 36.4 KB | ||
| 2025-05-16 13:29 |
Form 10-Q-For the quarterly period ended March 31, 2025
|
English | 1.1 MB | ||
| 2025-05-16 13:29 |
Form 10-Q-For the quarterly period ended March 31, 2025
|
English | 36.3 KB | ||
| 2025-04-29 11:13 |
FORM 8-K-entered into purchase agreement of 14,110,121 of Alpha Tau’s ordinary …
|
English | 400.3 KB | ||
| 2025-04-29 11:13 |
FORM 8-K-entered into purchase agreement of 14,110,121 of Alpha Tau’s ordinary …
|
English | 36.2 KB | ||
| 2025-04-09 16:13 |
Form 10K For the Fiscal Year Ended December 31, 2024
|
English | 2.0 MB |
Automate Your Workflow. Get a real-time feed of all Oramed Pharmaceuticals Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oramed Pharmaceuticals Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oramed Pharmaceuticals Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
